Drug Profile
AG 284
Alternative Names: AG-284Latest Information Update: 14 Aug 2007
Price :
$50
*
At a glance
- Originator Corixa Corporation
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 26 Aug 2003 AG 284 is still available for licensing (http://www.corixa.com)
- 26 Aug 2003 Suspended - Phase-II for Multiple sclerosis in USA (IV)
- 30 Jul 2002 This compound is still in active development